News for Monte Rosa Therapeutics, Inc. (GLUE)

Monte Rosa Therapeutics' stock falls as MRT-2359 faces challenges in targeting CRPC. Click here to read an analysis of GLUE stock now.

Monte Rosa Therapeutics Inc (GLUE) is set to release its Q4 2024 earnings on Mar 20, 2025. The consensus estimate for Q4 2024 revenue is $2.50 million, and the

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Q4 2024 Results Conference Call March 20, 2025 8:00 AM ETCompany ParticipantsAndrew Funderburk - Senior Vice...

Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of 162.16% and 374.06%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Results of the MRT-6160 Phase 1 SAD/MAD study demonstrate deep VAV1 degradation of greater than 90%, significant T and B cell functional inhibition as well as s

Monte Rosa Therapeutics reports $13.4M Q4 net income and strong cash position of $377M, ensuring funding into 2028 amidst key clinical milestones.

Company to present clinical results from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader MRT-6160 and Phase 1/2 study of MRT-2359 in MYC-driven s

**media[548317]**

BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. ( GLUE), a clinical-stage biotechnology company developing novel molecular glue degrad

One of Monte Rosa's main differentiating factors is its proprietary QuEEN platform to design new molecular glue degraders. Read why GLUE stock is a Buy.

On December 31, 2024, Avoro Capital Advisors LLC (Trades, Portfolio) executed a notable transaction involving Monte Rosa Therapeutics Inc. The firm reduced its

Initial clinical data from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader (MGD) MRT-6160 expected in Q1 2025 Additional clinical results from P

BOSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. ( GLUE), a clinical-stage biotechnology company developing novel molecular glue degrad

**media[491319]**

Monte Rosa Therapeutics appoints new board member

BOSTON, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. ( GLUE), a clinical-stage biotechnology company developing novel molecular glue degrad

Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

**media[489335]**

BOSTON, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. ( GLUE), a clinical-stage biotechnology company developing novel molecular glue degrad